Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal
squamous cell carcinoma. Aim to find the difference in efficacy and safety between
tirilizumab combined with concurrent chemoradiation and standard concurrent chemoradiation.
Concurrent chemoradiation is the standard treatment for elderly esophageal cancer.
Tirelizumab is the first-line and second-line standard treatment for advanced esophageal
squamous carcinoma. However, the effect of tirilizumab combined with concurrent
chemoradiation for elder with locally advanced esophageal squamous cell carcinoma is unkown.
In the study, the investigators plan to enroll 136 elderly subjects with locally advanced
esophageal cancer from five hospitals in China. The enrolled patients will be randomly
divided into two groups: tirilizumab combined with concurrent chemoradiation group
(Tislelizumab + radiotherapy + tigio) and concurrent chemoradiation group (radiotherapy +
tigio). The treatment efficiency and safety will be evaluated.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborators:
Henan Cancer Hospital Hunan Cancer Hospital Shanxi Province Cancer Hospital Sichuan Cancer Hospital and Research Institute The First Affiliated Hospital with Nanjing Medical University